IFPMA Adapting Innovation int 2 3 INDEX ADAPTIVE INNOVATION, INTELLECTUAL PROPERTY AND THE PUBLIC INTEREST: HOW PATENT EXTENSION LEADS TO MORE, BETTER AND SAFER MEDICINES INNOVATION: IT'S IN THE EYE OF THE BEHOLDER 10 PUTTING THEORY INTO PRACTICE: FIVE CASE STUDIES 11 Case Study 1: Zithromax SR [azithromycin] 12 Case Study 2: Neurontin [gabapentin] 14 Case Study 3: Procardia XL 16 Case Study 4: Agenerase 17...
author: Jupiter
IFPMA Adapting Innovation int 2 page 18
author: Jupiter
Hemispherx Biopharma, Inc. -- Research & Development: Clinical Trials: Chronic Fatigue Syndrome (CFS) : AMP 720 Home - | - Corporate Info - | - R & D - | - Products - | - Investor Relations - | - For the Patient - | - Careers at Hemispherx - - Should I Volunteer?Amprenavir (Agenerase) Note: 1 Trizivir counts for two of the required anti-retroviral drugs.
Hemispherx Biopharma, Inc. -- For The Patient- Clinical Trials: Chronic Fatigue Syndrome (CFS) : AMP 720 Home - | - Corporate Info - | - R & D - | - Products - | - Investor Relations - | - For the Patient - | - Careers at Hemispherx - - Should I Volunteer?Amprenavir (Agenerase) Note: 1 Trizivir counts for two of the required anti-retroviral drugs.
Vertex Pharmaceuticals Incorporated Download 11/11 Webcast (MP3) - - Systems Analyst , 6620-08B Director, Strategic Analysis , 6100-01B Clinical Safety Specialist , 1020-03B 11/18/05 Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated Agenerase, Lexiva, Vertex, amprenavir, AIDS, alliance, antiviral, apoptosis, autoimmune disease, Aventis, biology, biophysical chemistry, biophysics,...
Protease inhibitors (PIs) for HIV - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Protease inhibitors (PIs) for HIV - [Medication] - Quest Diagnostics Patient Health Library Protease inhibitors (PIs) for HIV - [Medication] - Quest Diagnostics Patient Health Library Immune system, Agenerase, amprenavir, antiretroviral agents,...
Key Company Facts- vrtx - 2004 and Beyond: Becoming a Major Drug Company Developing Potential Blockbusters: Vertex initiated clinical development of VX-950 in June 2004, and announced positive results of a Phase Ib clinical study in May 2005.
Biotech Tracker: Lexiva Approved - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Biotech Tracker news - Prodrug Protease Product Produces Profound Progress - - - - BioNews BioWeb Companies Products BioReports - - - - - - Prodrug Protease Product Produces Profound Progress October 24, 2002- Vertex (NASDAQ: VRTX ) announced that GW433908 (fosamprenavir, formerly VX-175) met a series of pivotal study endpoints that have set the stage for U.S.
Approved Products_2004.xls Number A pproval Date Trade Name Generic/ Chemical name Indication Company 1 Oct- 82 Humulin Human Insulin Type I Diabetes Lilly / Genentech 2 Oct- 85 Protro pin Human Growth Hormone Hypoptuitary dwarfism Genentech 3 Jun- 86 Intron A Interferon Al pha 2B Hairy Cell Leukemia Schering Plough / Biogen 4 Jun- 86 OKT- 3 Anti CD3 Mab Acute Trans plant Rejection JNJ / OrthoBiotech 5 Jun- 86...
author: Reijer
Approved Products_2004.xls page 3
author: Reijer
No Title UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.Agenerase," "Lexiva" and "Telzir" are registered trademarks of GlaxoSmithKlineplc.
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 104
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 84
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 62
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 59
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 40
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 24
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 22
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 10
author: Windows 9x/NT/2000/XP User
subject: None
No Title page 8
author: Windows 9x/NT/2000/XP User
subject: None
Collaborations - Major Collaborations Cystic Fibrosis Foundation Therapeutics, Inc.Agenerase and now pays Vertex royalties for sales of...
Vertex Pharmaceuticals Incorporated Regulatory Affairs Associate , 1200-02B Staff Investgator, Analytical Development , 2020-07B 1/25/05 Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated Agenerase, Lexiva, Vertex, amprenavir, AIDS, alliance, antiviral, apoptosis, autoimmune disease, Aventis, biology, biophysical chemistry, biophysics, biotech, biotechnology, breast cancer,...
Haberman Associates: Effective genomics-based drug discovery Effective genomics-based drug discovery: you still have to do the biology Allan B.
author: Allan B. Haberman
Collaborations - Partner Highlights Aventis S.A.
